Outcome of Board meeting held on November 12, 2025 for considering and approving the un-audited financial results for the quarter and half year ended September 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.4 pts less than Nifty Microcap 250 and 8.2 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Multibase India Ltd's board, at its meeting on November 12, 2025, approved the unaudited financial results for Q2 FY26 and H1 FY26 (ended September 30, 2025). Revenue from operations grew sharply year-on-year, with H1 FY26 revenue at approximately ₹5,692 lakhs versus around ₹4,161 lakhs in H1 FY25, a growth of roughly 37%. Despite this strong top-line performance, profit after tax fell significantly to ₹516.94 lakhs in H1 FY26 compared to ₹821.07 lakhs in H1 FY25, a decline of about 37%. Standalone Q2 FY26 PAT came in at ₹286.28 lakhs versus ₹428.80 lakhs in Q2 FY25 (around 33% YoY decline), and H1 FY26 EPS dropped to ₹4.09 from ₹6.51. The statutory auditor M/s. MSKA & Associates issued an unqualified (clean) limited review report with no qualifications or emphasis of matter.
Negative for shareholders — although revenue grew strongly, profitability collapsed with PBT falling ~37% even as topline rose ~37%, signalling severe margin compression and likely cost/pricing pressure. The sharp earnings decline despite sales growth may weigh on the stock in the near term.